CL-197

To investigate the safety and efficacy of long-acting glucagon like peptide-1 receptor agonists in overweight or obese patients with type 2 diabetes. Overweight or obese patients with type 2 diabetes from July 2021 to June 2022 were randomly divided into control group (metformin) and experimental group (metformin + dulaglitide or semaglutide). Repeated measures analysis of variance was used to compare Hemoglobin A1c, fasting plasma glucose and body mass index (BMI) of patients before treatment, 6 months and 12 months after treatment. The adverse reactions of patients before treatment and 12 months after treatment were analyzed. The time effect of Hemoglobin A1c, fasting plasma glucose and BMI in the control group (n = 35) and the experimental group (n = 32) were statistically significant (P < .001), and the intergroup effect of BMI was statistically significant (P < .05). The interaction effect of BMI was statistically significant (P < .001). The BMI level of the experimental group was lower than that of the control group at 6 and 12 months after treatment (P < .001). There was no significant difference in the incidence of adverse reactions between the 2 groups (P > .05). Long-acting glucagon like peptide-1 receptor agonists, such as dulaglitide and semaglutide, not only reduce glycosylated hemoglobin levels, but also significantly improve BMI in overweight or obese patients with type 2 diabetes.

Van Zuylen and colleagues provide an in-depth review of the medical literature as it pertains to duration of glucagon-like peptide-1 receptor agonist (GLP-1 RA) use and delayed gastric emptying.However, the notion that a longer duration of therapy attenuates delayed gastric emptying associated with GLP-1 RA use is weakly supported by the evidence provided and requires further examination before recommendations for clin. practice are prescribed.To explore the association between duration of GLP-1 RA therapy and increased residual gastric contents, we performed a confounder-adjusted logistic regression in the GLP-1 RA group, with increased residual gastric contents (primary outcome) as the dependent variable.Given this equivocal evidence on the duration of GLP-1 RA use and gastric emptying, we present a secondary anal. of our recently published study examining the association between GLP-1 RA use and the presence of increased residual gastric contents assessed by preoperative gastric ultrasound in patients undergoing anesthesia for elective procedures.We also performed a sensitivity anal. with the duration of GLP-1 RA therapy as a dichotomous variable (<12 wk: short-term use; nearly 12 wk: long-term use), as defined by van Zuylen and colleagues.Firstly, we recognize the potential utility of preoperative gastric ultrasound in providing easy-to-obtain and actionable information about gastric contents at the bedside, permitting individualized and informed perioperative airway management strategies for patients on GLP-1 RA therapy.Secondly, we recognize an urgent need for large prospective studies assessing the impact of longer preprocedural fasting times, duration of GLP-1 RA discontinuation before anesthesia, and duration of GLP-1 RA therapy on aspiration risk under anesthesia to inform future guidance on the perioperative management of patients on GLP-1 RA therapy.